1.Clinical observation and prognostic factors of renal pelvic tumor.
Woo Hyun KIM ; Myung Sik SHIN ; Hui Kyou PARK ; Kwang Don LEE ; Choong Sung CHUN
Korean Journal of Urology 1991;32(1):25-30
We reviewed 28 patients with renal pelvic tumor during the period from 1974 to 1989 and 17 patients were followed up. The over all survival rate at l, 2, and 3 years was 88%, 63%, and 50%, respectively, by the Kaplan-Meier method. The stage and the grade of the tumor were the most influencing factors on prognosis. Simultaneous tumors of ureter or bladder, non-visualizing kidney on excretory urography, duration of the gross hematuria more than 6 months showed relatively poor prognosis. But development of subsequent bladder tumor did not seem to influence on prognosis.
Hematuria
;
Humans
;
Kidney
;
Prognosis
;
Survival Rate
;
Ureter
;
Urinary Bladder
;
Urinary Bladder Neoplasms
;
Urography
2.Minimum Specimen Volume Analysis of ABO/RhD Typing and Unexpected Antibody Screening Using an Automated Immunohematology System DAYmate S.
Tae Yeul KIM ; Dong Woo SHIN ; Byeong Hui SON ; Ji Sang KANG ; Yousun CHUNG ; Dae Hyun KO ; Yun Ji HONG ; Hyungsuk KIM ; Kyoung Un PARK ; Kyou Sup HAN
Korean Journal of Blood Transfusion 2018;29(2):159-170
BACKGROUND: Phlebotomy performed for laboratory testing has the potential to cause anemia in newborns and infants. This study investigated the minimum specimen volume required for an automated immunohematology analyzer DAYmate S. METHODS: Three combinations of tubes were evaluated: I. 6 mL EDTA tube, II. 0.5 mL microtainer (on top of 3 mL EDTA tube), and III. 1 mL sample cup (on top of 6 mL EDTA tube). ABO/RhD cell typing was done using centrifuged red cells; unexpected antibody screening was carried out using plasma, and Type & Screening was conducted using whole blood samples. The lowest specimen volume capable of performing 10 repetitive tests without errors was investigated. RESULTS: ABO/RhD cell typing could be performed from I. 30 μL, II. 25 μL, and III. 25 μL. Unexpected antibody screening could be performed from I. 170 μL, II. 150 μL, and III. 140 μL. According to the hematocrit levels, Type & Screening could be performed from 30%, I&III 650 μL, II. 800 μL; 40%, I&III 650 μL, II. 900 μL; and 50%, I&III 1,000 μL, II. Testing using specimen volumes below 1,000 μL was difficult. CONCLUSION: By separating red cells and plasma, pre-transfusion testing of ABO/RhD cell typing and unexpected antibody screening could be conducted with very small specimen volumes using DAYmate S compared to Type & Screening using whole blood. The application of small-sized sample tubes was more competitive and this is expected to be very useful for preventing iatrogenic anemia in neonates and infants less than 4 months old.
Anemia
;
Edetic Acid
;
Hematocrit
;
Humans
;
Infant
;
Infant, Newborn
;
Mass Screening*
;
Phlebotomy
;
Plasma